Sanofi-Pasteur chases AZ and GSK round the quad to catch up in 'flu vaccine race
This article was originally published in Scrip
Executive Summary
Sanofi-Pasteur has presented Phase III data for a quadrivalent version of its Fluzone influenza vaccine as its chases AstraZeneca and GlaxoSmithKline to market in this new four-pronged approach to seasonal flu prevention.